Patient Home
Welcome to Health Vidya. Discover trusted care and your own health — all in one place.
These highlights do not include all the information needed to use COREG CR safely and effectively. See full prescribing information for COREG CR. COREG CR® (carvedilol phosphate) Extended-release CapsulesInitial U.S. Approval: 1995
Medication labelWhy this: Advisory · dailymed-prescription
COREG CR is indicated for the treatment of mild-to-severe chronic heart failure of ischemic or cardiomyopathic origin, usually in addition to diuretics, ACE inhibitors, and digitalis, to increase survival and, also, to reduce the risk of hospitalization [see Clinical Studies (14.1)]. COREG CR is indicated to reduce cardiovascular mortality in clinically stable patients who have survived the acute phase of a myocardial infarction and have a left ventricular ejection fraction of ≤40% (with or without symptomatic heart failure) [see Clinical Studies (14.2)]. COREG CR is indicated for the management of essential hypertension [see Clinical Studies (14.3, 14.4)]. It can be used alone or in combination with other antihypertensive agents, especially thiazide-type diuretics [see Drug Interactions (7.2)].
- generic_name
- carvedilol phosphate
- product_names
- carvedilol phosphate
- ndc
- 54868-6019, 0007-3370, 54868-6019-0, 54868-6019-1, 54868-0106, 0007-3371, 54868-0106-1, 54868-0106-2, 54868-5869, 0007-3372, 54868-5869-0, 54868-5869-1, 54868-5771, 0007-3373, 54868-5771-0, 54868-5771-1
- group
- drugs
- license
- us-gov-pd
- attribution
- Courtesy of the National Library of Medicine
- reviewed
- 2026-09-18
- language
- en